Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Microbiologics SARS-CoV-2 virus antigen controls

November 2021—Microbiologics has launched its SARS-CoV-2 Whole Virus Antigen Control, which can be used in the point-of-care setting for the detection of SARS-CoV-2 antigens and for monitoring the extraction, amplification, and detection in nucleic acid testing. In antigen-based applications, the high titer formula provides a clear positive reaction to monitor the detection of SARS-CoV-2 viral antigens. Each kit contains six individually packaged lyophilized swabs.

Roche launches three respiratory panels in CE markets

November 2021—Roche launched in the CE market three molecular PCR diagnostic test panels to simultaneously detect and differentiate flu A, flu B, and respiratory syncytial virus; adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and parainfluenza 1, 2, 3, and 4. The tests can be run together or individually from a single nasopharyngeal swab specimen and run on the Cobas Omni Utility Channel for use with the Cobas 6800/8800 systems.

BD FACSymphony A1 Cell Analyzer

October 2021—BD launched the BD FACSymphony A1 Cell Analyzer, a fluorescence-activated cell analyzer that offers advanced research capabilities in a benchtop design. Fluorescence-activated cell sorter (FACS) technology enables precise isolation of selected single cells from complex samples.

Siemens launches Sysmex CN-3000, CN-6000 hemostasis systems

October 2021—Siemens Healthineers has launched Sysmex’s CN-3000 and CN-6000 hemostasis systems for mid- and high-volume coagulation testing. A broad menu of Siemens’ routine and specialty coagulation assays that help identify blood coagulation disorders such as abnormal blood clotting or bleeding, including Siemens’ Innovance Anti-Xa assay for heparin and direct oral anticoagulant testing, can be performed on the CN-3000 and CN-6000 instruments.

Cepheid gets EUA for Xpert Xpress CoV-2/Flu/RSV Plus

October 2021—Cepheid received FDA emergency use authorization for its Xpert Xpress CoV-2/Flu/RSV Plus, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, flu A, flu B, and respiratory syncytial virus infections from a single patient sample. The Plus version of the test provides three gene targets for SARS-CoV-2 detection—N2, E, and RdRP. The test is designed for use on any GeneXpert system and results are delivered in about 36 minutes.

Mesa Labs to acquire Agena

October 2021—Mesa Laboratories has entered into a definitive agreement to acquire Agena Bioscience for a cash price of $300 million, subject to customary purchase price adjustments. The transaction is expected to be completed by Dec. 31 and is subject to customary conditions, including receipt of applicable regulatory approvals.

Thermo Fisher expands hematology-oncology NGS portfolio

October 2021—Thermo Fisher Scientific announced a suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T cells and B cells. Using proprietary Ion AmpliSeq technology, the pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity.

FDA grants EUA to next-gen TaqPath COVID-19 assays

October 2021—Thermo Fisher Scientific announced FDA emergency use authorization of the TaqPath COVID-19 Fast PCR Combo Kit 2.0 and TaqPath COVID-19 RNase P Combo Kit 2.0. Both kits are updated versions of tests, with increased genomic target redundancy to ensure continued accuracy as SARS-CoV-2 mutates.

Steripath Micro available for use in children’s hospitals

October 2021—Magnolia Medical Technologies announced the commercial availability of its Steripath Micro Initial Specimen Diversion Device designed for use in children’s hospitals. Steripath Micro is an FDA 510(k)-cleared device with the specific indication to reduce blood culture contamination. The small, lightweight device requires less than 1 mL of blood for patients with limited volumes or difficult intravenous access. The company says Steripath Micro has shown a zero percent contamination rate in two leading children’s hospitals during a three- month period.

MARKETPLACE

TRENDING